Provided by Tiger Fintech (Singapore) Pte. Ltd.

RenovoRx Inc

0.8350
+0.085011.33%
Volume:307.22K
Turnover:250.35K
Market Cap:30.60M
PE:-2.31
High:0.8432
Open:0.7700
Low:0.7700
Close:0.7500
52wk High:1.69
52wk Low:0.7006
Shares:36.65M
Float Shares:30.09M
Volume Ratio:1.81
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3612
EPS(LYR):-0.3958
ROE:-107.11%
ROA:-54.82%
PB:2.88
PE(LYR):-2.11

Loading ...

RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating

TIPRANKS
·
Nov 16

RenovoRx Earnings Call: Positive Momentum and Strategic Growth

TIPRANKS
·
Nov 15

RenovoRx Enters Capital on Demand Sales Agreement

TIPRANKS
·
Nov 15

BRIEF-RenovoRx May Offer Securities For Up To $50 Million - SEC Filing

Reuters
·
Nov 15

RenovoRx Inc - May Offer Securities for up to $50 Mln - SEC Filing

THOMSON REUTERS
·
Nov 15

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)

TIPRANKS
·
Nov 15

RenovoRx price target lowered to $3 from $3.50 at Alliance Global

TIPRANKS
·
Nov 15

RenovoRx Expands Reach with RenovoCath Approval

TIPRANKS
·
Nov 14

Cancer drug developer RenovoRx's Q3 net loss widens

Reuters
·
Nov 14

RenovoRx Q3 EPS $(0.08), Inline, Sales $266.000K Miss $405.333K Estimate

Benzinga
·
Nov 14

BRIEF-RenovoRx Q3 Net Income USD -2.912 Million

Reuters
·
Nov 14

RenovoRx Inc: Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn

THOMSON REUTERS
·
Nov 14

Press Release: RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Dow Jones
·
Nov 14

RenovoRx Treats First Patient in RenovoCath Clinical Trial

Reuters
·
Nov 12

RenovoRx Strengthens Scientific Advisory Board (SAB) With Pancreatic Cancer Expert Timothy Donahue, Md

THOMSON REUTERS
·
Nov 06

Press Release: RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Dow Jones
·
Nov 06

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

GlobeNewswire
·
Nov 04

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

GlobeNewswire
·
Oct 27

RenovoRx Expands Scientific Advisory Board With Internationally Renowned Interventional Oncologist, Thierry De BaÈRe, Md, Phd

THOMSON REUTERS
·
Oct 09

Press Release: RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Dow Jones
·
Oct 09